Project Grant R01CA300205
Award Date 9/24/25
Completion Date 8/31/29
Dollars Obligated $2.7M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- This federal Project Grant award of $714,317.00 from the National Cancer Institute (NCI), under the Cancer Biology Research program (CFDA 93.396), supports research at the Icahn School of Medicine at Mount Sinai (ISMMS) in New York. The goal is to investigate the mechanisms linking epithelial-mesenchymal transition (EMT), anoikis resistance, and the tumor microenvironment in the progression of metastatic castration-resistant prostate cancer. Key research objectives include determining how...
- The National Cancer Institute awarded a Project Grant under CFDA 93.396 - Cancer Biology Research to Cornell University in the amount of $576,337 on August 11, 2025. The project, titled "The Integrated Mechanobiology and Glycobiology of Bone Metastasis", aims to study how the mineral content of bone matrix influences early-stage metastasis of breast cancer cells. The research team will investigate the mechanisms by which bone mineral density regulates the behavior of disseminated tumor...
- This federal Project Grant award for $2,679,816.00, provided by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), supports four integrated research projects that aim to address key aspects of mutant p53 and its role in tumor metastasis. The funded research, led by principal investigator James Manfredi, focuses on systematic studies of mutant p53 allelic variation, mechanisms of the hot-spot mutant p53R175H in tumor metastasis, defining the roles of mutant p53...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $700,690.00 to Health Research, Inc. in Buffalo, NY to support research aimed at deciphering the molecular mechanisms of breast cancer bone metastasis. The 5-year project (04/01/2025 - 03/31/2030) seeks to unravel the biological transition from early-stage microscopic bone metastases to established macro-bone metastases, with a focus on understanding the role of the YAP/TAZ...
- The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) has awarded a $169,000 Project Grant to the Icahn School of Medicine at Mount Sinai (ISMMS) to investigate the role of histone variant MacroH2A in shaping the tumor microenvironment and immune response in melanoma. The research aims to characterize how the loss of MacroH2A leads to increased activation and inflammatory gene expression in cancer-associated fibroblasts, and how this impacts tumor initiation and the anti-tumor...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $147,083 to the Icahn School of Medicine at Mount Sinai to conduct research on "Deconstructing Pathogenic Myelopoiesis in Cancer Immunosuppression and Treatment Resistance". The key objectives are to study the epigenetic regulation and priming of regulatory pathways in tumor-educated bone marrow myeloid progenitors, with a focus on understanding how the NRF2 oxidative...
- The U.S. National Cancer Institute awarded a Project Grant in the amount of $1,056,000.00 to the Sloan-Kettering Institute for Cancer Research, a leading cancer research organization located in New York. The grant, awarded under the federal Cancer Treatment Research program (CFDA 93.395), supports research focused on overcoming resistance to targeted therapies in breast cancer. The key objectives of the research project include elucidating the mechanisms underlying breast cancer plasticity and...
- The National Cancer Institute (NCI) awarded a $645,323 Project Grant under the Cancer Biology Research program (CFDA 93.396) to Washington University to conduct research on the "Mechanism of Acid Signaling in Bone Organ Metastases on Tumor and Myeloid Cell Evolution Towards Immune Suppression and Tumor Progression." The 5-year research project from February 1, 2025 to January 31, 2030 will investigate how breast cancer cells produce factors that induce an acidic bone marrow...
- The National Cancer Institute, a component of the National Institutes of Health, awarded a $684,877 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Icahn School of Medicine at Mount Sinai. The grant will support a multi-scale analysis of the tumor microenvironment in non-muscle invasive bladder cancer to identify novel therapeutic targets for patients resistant to the standard first-line treatment, Bacillus Calmette-Guerin (BCG). The research project aims to generate...
- The National Cancer Institute awarded a $2,489,032 Project Grant to the Sloan-Kettering Institute for Cancer Research on August 1, 2025 under the Cancer Biology Research program (CFDA 93.396). The grant will fund a 5-year research program to investigate the role of lipid metabolism in ferroptosis, a novel cell death process, and explore innovative therapeutic approaches for treating aggressive, drug-resistant cancers. The program consists of three highly integrated projects led by researchers at...